May 11, 2021
Company Expands Global Reach with Latest Endovascular Aneurysm Repair (EVAR) Technology
IRVINE, Calif.—May 11, 2021—Endologix LLC today announced the first implant of its ALTO® Abdominal Stent Graft in Canada following recent approval from Health Canada. ALTO was also recently approved for commercial sale in Argentina.
“We are excited to extend the global reach of ALTO, which is now available in Europe, New Zealand, Canada and Argentina, as well as the U.S.,” said Prof. Matt Thompson, chief medical officer of Endologix. “ALTO fulfills an unmet clinical need, offering a highly differentiated endovascular treatment option for patients with AAA and offers the ability to treat the largest proportion of patients within the approved indications for use.”